A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement

OVARTIS FARMA0 个研究点目标入组 150 人开始时间: 2005年10月24日最近更新: 2013年1月7日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: OVARTIS FARMA
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Inclusion Criteria 1. Male or female patients >18 years of age who have signed an informed consent 2. Patients with type 1 or type 2 diabetes mellitus diagnosed ≥24 months prior to screening and a documented history of stable HbA1c ≥6.5% and ≤9.5% at the time of screening (stable HbA1c values are defined as those that do not differ at monthly assessments by more than 0.5% HbA1c). Any one of the following will be considered to be sufficient evidence that diabetes is present ? Current regular use of insulin for the treatment of diabetes ? Current regular use of oral antihyperglycemia agents for the treatment of diabetes ? Documented diabetes by ADA and/or WHO criteria (see Study Operations Manual) 3. Patients with diabetic macular edema with center involvement in at least one eye, including those with focal or diffuse DME, as demonstrated with stereoscopic fundus photography, fluorescein angiography and optical coherence tomography within 28 days of the baseline treatment. For this eye to achieve eligibility statue it must fulfill the following three criteria at Visit 1: ? The central macular thickness must be ≥300 μm in the center subfield, as assessed by OCT and confirmed by the central reading center. ? BCVA score between 69 and 39 letters, inclusively, using ETDRS-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/40 to 20/160) ? Decrease in vision is due to foveal thickening from DME and not due to other causes, in the opinion of the investigator 4. Patients with DME without previous laser photocoagulation or patients who have been treated at least 6 months preceding Day 1 with mild focal laser photocoagulation consisting of no more than 30 laser burns that are at least 500 μm from the center of the fovea will be allowed to enter the study. 5. Only one eye will be selected for study treatment (study eye). If both eyes are eligible, the one with the worse visual acuity, as assessed at Visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment. The medical reason for selecting the study eye having the better visual acuity must be described in the eCRF 6. The BCVA score in the non-study eye (fellow eye) must be ≥24 letters (approximate Snellen equivalent of 20/320) at Visit 1 7. Patients for whom, in the opinion of the investigator, laser photocoagulation in the study eye can be withheld for at least 3 months after randomization 8. Willing to return for all scheduled visits
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. A condition that in the opinion of the investigator would preclude a patient's participation in the study, e.g., unstable medical status including glycemic control and blood pressure. Patients in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled. Patients with hypertension for whom a change in antihypertensive treatment was initiated within 2 months preceding Day 1 should not be enrolled unless blood pressure is maintained for at least 1 month prior Day 1 below 150/95 mm Hg by antihypertensive treatment 2. History of systemic (e.g., oral, IV, IM, epidural, bursal) corticosteroids within 4 months prior to randomization or topical, rectal, or inhaled corticosteroids in current use more than 2 times per week

研究者

发起方

OVARTIS FARMA

相似试验

进行中（未招募）

1 期

EUCTR2005-000487-11-GBovartis Pharma Services AG

进行中（未招募）

不适用

A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement - RESOLVEMale and female patients >18 years of age with either type 1 or type 2 diabetes mellitus with stable HbA1c levels between 6.5 and 10% and diabetic macular edema with center involvement in at least one eye.

EUCTR2005-000487-11-DKovartis Pharma Service AG150

进行中（未招募）

不适用

EUCTR2005-000487-11-PTovartis Pharma Service AG150

进行中（未招募）

1 期

EUCTR2005-000487-11-DEovartis Pharma Service AG150

进行中（未招募）

不适用

EUCTR2005-000487-11-ESovartis Farmacéutica, S.A.150